NJOY Sues FDA Over Delayed Ruling on Flavored Disposable Vapes

Aug.24.2025
NJOY Sues FDA Over Delayed Ruling on Flavored Disposable Vapes
Altria’s subsidiary NJOY has sued the U.S. Food and Drug Administration (FDA) and the U.S. Department of Health and Human Services (HHS), alleging prolonged delays in ruling on its appeal for flavored disposable vapes. NJOY argues the products are identical to authorized versions and backed by scientific data and safeguards, yet the review has taken far beyond statutory limits, blocking lawful products while illicit ones flood the market.

Key Points

 

Lawsuit Filed

  • NJOY (Altria subsidiary) and Louisiana retailers filed suit on Aug. 21, 2025, in the Western District of Louisiana.

 

Defendants Named

  • FDA, U.S. Department of Health and Human Services (HHS), FDA Commissioner Martin Makary, HHS Secretary Robert F. Kennedy Jr., Acting CTP Director Bret Koplow.

 

Case Background

  • FDA denied flavored NJOY DAILY PMTAs in June 2022 but approved tobacco and later menthol variants; the appeal has been pending for nearly three years.

 

Evidence Submitted

  • Longitudinal cohort study (3,600+ adults) showing higher switching for flavored products;
  • Youth perception studies;
  • Strict age-verification and sales restrictions;
  • FDA staff assessments supporting NJOY’s data.

 

Main Allegations

  • Inconsistent standards, disregard of evidence, refusal to weigh safeguards, excessive delay, and market imbalance favoring illicit products.

 


 

 

[2Firsts, August 24, 2025] NJOY, LLC, a subsidiary of Altria, together with several Louisiana-based distributors and retailers, filed a lawsuit on August 21 in the U.S. District Court for the Western District of Louisiana, Lafayette Division. The defendants include the U.S. Food and Drug Administration (FDA), the U.S. Department of Health and Human Services (HHS), as well as FDA Commissioner Martin Makary, HHS Secretary Robert F. Kennedy, Jr., and Acting Director of FDA’s Center for Tobacco Products (CTP) Bret Koplow.

 

The plaintiffs allege that the FDA has failed to act on NJOY’s supervisory appeal concerning its flavored disposable vape products, leaving the matter unresolved for nearly three years. According to NJOY, this delay has kept lawful products out of the market while illicit flavored disposables have flourished across the United States.

 

 

Case Background

 

 

In March 2020, NJOY submitted eight PMTAs for NJOY DAILY products, including two tobacco, two menthol, and four flavored variants: Blue + Black Berry 4.5%, EXTRA Blue + Black Berry 6%, Watermelon 4.5%, and Tropical Twist 4.5%.

 

In June 2022, the FDA granted marketing orders for the tobacco variant (and later for menthol) but denied the flavored applications. NJOY stressed that these products are identical in design and composition to the authorized versions, differing only in flavor. The company filed a supervisory appeal in October 2022, which remains undecided to date.

 

NJOY Sues FDA Over Delayed Ruling on Flavored Disposable Vapes
Case Information | Screenshot from justia.com

 

 

NJOY’s Evidence

 

 

To support its applications and appeal, NJOY submitted a broad package of scientific evidence and market restrictions:

 

  • Longitudinal Cohort Study: Followed over 3,600 adult DAILY users, showing that about one in five achieved complete switching after three months. Flavored variants demonstrated higher switching rates than tobacco and menthol.

 

  • Switching Rate Data: The three flavored variants showed 40–113% higher complete switching at three months and 29–68% higher at six months compared to tobacco/menthol.

 

  • Youth Studies: Among 1,000 adolescents aged 13–17, use of NJOY products showed no statistically significant increase; in a perception survey of 3,000+ teens, overall interest was low with only minor differences between flavors.

 

  • Market Restrictions: NJOY committed to selling only through licensed retailers, enforcing strict online and offline age-verification, and implementing additional sales and reporting limits.

 

  • Internal FDA Documents: Obtained via FOIA, internal assessments from FDA’s Office of Health Communication and epidemiology staff concluded that NJOY’s restrictions exceeded prior benchmarks and that flavored variants were associated with higher switching rates.

 

 

NJOY’s Main Allegations Against FDA

 

 

According to the complaint, NJOY argues that FDA’s handling of its applications and appeal is flawed in several key respects:

 

  • Inconsistent Standards: Tobacco and menthol products were authorized, while compositionally identical flavored products were denied.

 

  • Disregard of Evidence: FDA failed to give due weight to NJOY’s longitudinal data and youth-specific studies.

 

  • Rejection of Safeguards: NJOY’s stringent marketing and age-verification measures were not meaningfully considered.

 

  • Procedural Delay: The supervisory appeal has been pending since October 2022, effectively creating a “de facto flavor ban.”

 

  • Market Imbalance: Lawful products remain sidelined, while illicit flavored disposables dominate U.S. retail.

 

NJOY also underscored the severe imbalance in timing. Under the Family Smoking Prevention and Tobacco Control Act, FDA is expected to act on PMTAs within 180 days. Instead, NJOY’s flavored applications were denied only after 802 days—4.5 times the statutory period. Even more striking, its supervisory appeal has now been pending for 1,003 days, or 5.6 times longer than the statutory timeframe. NJOY contends that a review based on the existing record, typically involving only internal coordination and administrative file review, should not take longer than the initial PMTA assessment.

 

 

NJOY–FDA Key Timeline of Interactions

 

 

  • 2020-03-30: NJOY submits eight DAILY PMTAs, including four flavored variants.
  • 2020-12-17: FDA issues deficiency letter, asking for stronger evidence on flavored variants.
  • 2021-03-04: NJOY responds, providing six-month longitudinal data.
  • 2022-06-10: FDA issues MDOs for flavored products; grants MGO for tobacco variant.
  • 2022-10-17: NJOY files supervisory appeal.
  • 2022-11-07: Then-CTP Director Brian King accepts the appeal and delegates to Shawn Fultz.
  • 2023-01-11: NJOY holds virtual meeting with FDA/CTP; no substantive outcome.
  • 2024-01-17, 2025-04-22, 2025-07-30: NJOY sends three follow-up letters urging resolution; no response.
  • 2025-05: Bret Koplow appointed Acting Director of CTP.
  • 2025-08-21: Lawsuit formally filed in the Western District of Louisiana.

 

NJOY Sues FDA Over Delayed Ruling on Flavored Disposable Vapes

 

 

NJOY’s Requested Relief

 

 

The plaintiffs ask the court to declare FDA’s delay unlawful under the Administrative Procedure Act, to compel the agency via injunction or writ of mandamus to issue a prompt decision on the supervisory appeal, and to award costs and attorney’s fees while retaining jurisdiction for oversight.

 

2Firsts will continue to closely follow this case and provide timely updates.

 

Cover image generated by ChatGPT

Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board Backs New Vape Nicotine Exemption After Unanimously Opposing 2023 Proposal
Malaysia's Poisons Board has endorsed Health Minister Dzulkefly Ahmad's proposal to exempt liquid nicotine used in vaping products from the Poisons List, according to a November 2, 2026, report by CodeBlue. The Board unanimously opposed a similar proposal in 2023, but the government proceeded with the exemption. The Kuala Lumpur High Court invalidated the 2023 decision in May 2026, and the government withdrew its appeal in August. No new ministerial order has been published. The development raises questions about the interaction between Malaysia's two regulatory frameworks and the treatment of RM354.51 million in excise duties collected on e-cigarette and vape products between May 2023 and June 11, 2026.
Regulations
Nov.03
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands Sees Double-Digit NGP Growth as Sixth Year of Tobacco Revenue Gains Backs £1.5 Billion Buyback
Imperial Brands reaffirmed its FY26 guidance in its October 8 pre-close trading update, forecasting double-digit net revenue growth in next-generation products and share gains across heated tobacco, vape and modern oral. Tobacco net revenue is expected to grow at a low-single-digit rate, marking a sixth consecutive year of growth. The company has completed its £1.45 billion FY26 share repurchase and announced a £1.5 billion buyback for FY27. Group adjusted operating profit is expected to increase 3% to 5%, while free cash flow is forecast to exceed £2.2 billion.
Oct.09
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
On-Site Report | After FDA Announces Review of PMTA Framework, CTP Director Details Reform Priorities
FDA CTP Director Bret Koplow used his FDLI keynote in Washington to outline how the agency is rethinking the PMTA framework. He discussed category-specific review, nicotine pouch and sPMTA pilots, AI-assisted review, a 70% reduction in pending applications, and a major staffing constraint: CTP currently has only nine scientific review teams. He also reaffirmed tobacco harm reduction while stressing youth protection, flavored products, risk communication, and the challenge of unauthorized e-cigarettes.
Regulations
Oct.06
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Global Starts Debt Refinancing Four Months After Nasdaq Listing With About $400 Million Notes Expected
AIR Limited, a wholly owned subsidiary of AIR Global, has launched an offering of U.S. dollar-denominated senior unsecured notes, with proceeds primarily intended to repay its existing term loan and revolving credit facility. AIR has not disclosed the final size, maturity or coupon; Refinitiv, citing Moody's, reported an expected issuance of approximately $400 million and a Ba3 rating. AIR had about $412.4 million outstanding under the two bank facilities at June 30 and net debt of $344.8 million. In the first half of 2026, AIR's Al Fakher-led flavored shisha molasses business generated about 99% of company revenue, while New Growth Categories including Crown Switch produced $2.2 million in revenue and remained loss-making on an adjusted EBITDA basis.
Sep.23
Russia Expands Temporary Administration of JTI Assets in Second Round: From Four to All Seven Russian Entities, With Approximately $9.5 Billion in Related Assets
Russia Expands Temporary Administration of JTI Assets in Second Round: From Four to All Seven Russian Entities, With Approximately $9.5 Billion in Related Assets
Japan Tobacco Inc. (JT) confirmed on November 9, 2026, that all seven of its Russian entities had been placed under temporary administration after a second presidential decree added three companies to the four designated a day earlier. The additional entities are associated with importing, management, holdings and the former supply of Ploom heated-tobacco devices. JT disclosed approximately ¥1.5 trillion in Russian business-related assets as of September 30, including ¥360 billion in cash and deposits, and approximately ¥200 billion in liabilities. Under its revised FY2026 forecast, Russia accounts for about 25% of adjusted operating profit. JT said operations in Russia were continuing, while the financial impact remained under assessment.
company
Nov.09
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
UK ONS Data: Vaping Rate Among Women Aged 25–34 Reaches 18.3%, Compared With 14.4% for Men
The vaping rate among women aged 25 to 34 in Great Britain reached 18.3% in 2025, up from 13.7% in 2024 and 8.3% in 2020, according to data from the Office for National Statistics (ONS). The figure was the highest for this group since records began in 2014 and exceeded the 14.4% recorded among men of the same age. Adults aged 25 to 34 also overtook those aged 16 to 24 as the age group with the highest vaping prevalence. Overall, about 5.4 million adults in Great Britain used e-cigarettes in 2025, broadly unchanged from the previous year.
DATA
Oct.13